ANTXR1 (anthrax toxin receptor 1) Blocking Peptide (the middle region of protein) (100ug)

This is a synthetic peptide designed for use in combination with anti-ANTXR1 antibody (Catalogue #: ARP50040_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Prices direct from Aviva Systems Biology Incorporated

Quick response times

Exclusive Absave savings/discounts

SPECIFICATIONS

Size

100 ug

Format

Lyophilized powder

Presku

AAP50040

Target

ANTXR1 is a type I transmembrane protein and is a tumor-specific endothelial marker that has been implicated in colorectal cancer. ANTXR1 has been shown to also be a docking protein or receptor for Bacillus anthracis toxin, the causative agent of the disease, anthrax. The binding of the protective antigen (PA) component, of the tripartite anthrax toxin, to this receptor protein mediates delivery of toxin components to the cytosol of cells. Once inside the cell, the other two components of anthrax toxin, edema factor (EF) and lethal factor (LF) disrupt normal cellular processes.The protein encoded by this gene is a type I transmembrane protein and is a tumor-specific endothelial marker that has been implicated in colorectal cancer. This protein has been shown to also be a docking protein or receptor for Bacillus anthracis toxin, the causative agent of the disease, anthrax. The binding of the protective antigen (PA) component, of the tripartite anthrax toxin, to this receptor protein mediates delivery of toxin components to the cytosol of cells. Once inside the cell, the other two components of anthrax toxin, edema factor (EF) and lethal factor (LF) disrupt normal cellular processes. Three alternatively spliced variants have been described.

Weight

60kDa

Gene Id

84168

Alternative Names

ATR; FLJ10601; FLJ11298; FLJ21776; TEM8